etoricoxib (Arcoxia)
Jump to navigation
Jump to search
Introduction
In pipeline. Mid 2002; as of 2011, still not FDA-approved.
Adverse effects
- long-term risk for adverse cardiovascular events similar to diclofenac[3]
- edema, heart failure, hypertension more common with etoricoxib than diclofenac
- adverse gastrointestinal events less common with etoricoxib than diclofenac (no differences in serious complications)[4]
More general terms
References
- ↑ Prescriber's Letter 8(11):61 2001
- ↑ Prescriber's Letter 12(3): 2005 COX-2 Inhibitor Safety: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210301&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Cannon CP et al, for MEDAL Steering Committee Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthrities Long-term (MEDAL) programme: A randomised aomparison. Lancet 2006, 368:1771 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17113426
Garcia Rodriguez LA and Patrignani P The ever growing story of cyco-oxygenase inhibition. Lancet 2006, 368:1745 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17113403 - ↑ 4.0 4.1 Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17292766
Drenth JP, Verheugt FW. Do COX-2 inhibitors give enough gastrointestinal protection? Lancet. 2007 Feb 10;369(9560):439-40. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17292743